Recursion reports positive Phase 1/2 data for REC-1245, Phase 2 proof-of-concept for REC-4881

Recursion disclosed preliminary Phase 1/2 clinical data for REC-1245, a first-in-class RBM39 degrader. The drug was well-tolerated in 16 patients with solid tumors, with no dose-limiting toxicities observed to date and most adverse events being Grade 1 or 2. Pharmacokinetic analysis showed predictable, dose-dependent exposure, and pharmacodynamic assessments confirmed target engagement. Dose escalation continues to determine the recommended Phase 2 dose.

Recursion reported Q1 2026 results with cash of $665.2 million (down from $753.9 million at year-end 2025), revenue of $6.5 million (down from $14.7 million in Q1 2025), and net loss of $117.5 million (improved from $202.5 million in Q1 2025). Operating cash burn was $81.1 million, down from $132.0 million in Q1 2025. The company reiterated guidance for less than $390 million operational cash burn in 2026, supporting runway into early 2028 without additional financing.

Recursion reiterated its 2026 guidance for operational cash burn of less than $390 million and confirmed that its current cash position supports operations into early 2028 without additional financing. This provides visibility into the company's capital runway and operating efficiency improvements.

Recursion reported $665 million in cash, cash equivalents, and restricted cash as of March 31, 2026. The company achieved approximately 30% reduction in year-over-year cash operating expense to $85 million in Q1 2026, and reiterated 2026 cash operating expense guidance of less than $390 million. The company expects its cash runway to extend into early 2028 without additional financing.

Recursion disclosed early Phase 1 dose escalation data for REC-1245, a first-in-class RBM39 degrader targeting solid tumors and lymphoma. The drug was well-tolerated with no dose-limiting toxicities (DLTs) across all evaluated doses to date in 16 patients. Over 90% of treatment-related adverse events were Grade 1 or 2, with the most common being fatigue, constipation, nausea, and vomiting. The drug demonstrated predictable, dose-dependent exposure supportive of once-daily dosing. An update is expected in the second half of 2026.

Recursion dosed the first patient in the Phase 1 ENLYGHT trial for REC-4539, an LSD1 inhibitor designed to address solid tumors including small cell lung cancer. The drug was precision-designed with a shorter predicted human half-life and reversible mechanism of action to reduce the risk of dose-limiting thrombocytopenia observed with prior LSD1 inhibitors. Early monotherapy safety and pharmacokinetic data are expected in the second half of 2027.

Recursion appointed Dr. Vicki Goodman as Chief Medical Officer. Dr. Goodman brings over two decades of oncology drug development experience from Merck, Bristol Myers Squibb, GlaxoSmithKline, Exelixis, and Mural Oncology, including work on KEYTRUDA, OPDIVO, YERVOY, and dabrafenib. She previously served as a Medical Officer at the FDA and will oversee clinical development, regulatory affairs, and development decisions for Recursion's pipeline.